Candesant Biomedical Announces $35M In Series B Financing To Advance Commercialization Of Brella™, The First And Only Fda-Cleared 3-Minute Sweatcontrol Patch™
Amount Raised
$35 Million
Round Type
Series B
NashvilleManufacturingBiotechnologyHealth CareMedicalMedical DeviceInvestors
Description
Candesant Biomedical, Inc. ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive treatments for hyperhidrosis or excessive sweating, today announced the closing of a Series B financing, raising a total of $35 million to advance the commercialization of Brella, the first-and-only FDA-cleared 3-Minute SweatControl Patch. The financing was led by KCK MedTech, a venture capital firm specializing in medical technologies, along with other investors including Polaris Partners, Astia Fund, and Correlation Ventures.
Quick answer
Candesant Biomedical, Inc. raised $35 Million in a Series B round, dated June 6, 2023. Investors: Correlation Ventures, Astia Fund, Polaris Partners and Kck Med Tech. Candesant Biomedical, Inc. is based in Nashville, Arkansas, United States.
- How much did Candesant Biomedical, Inc. raise?
- Candesant Biomedical, Inc. raised $35 Million in a Series B round on June 6, 2023.
- Who invested in Candesant Biomedical, Inc?
- Correlation Ventures, Astia Fund, Polaris Partners and Kck Med Tech are named as investors in this round.
- What does Candesant Biomedical, Inc. do?
- Candesant Bio is a clinical stage company that is driving research and development of its novel, investigational sweat control patch designed to offer underarm sweat relief with no downtime.
- Where is Candesant Biomedical, Inc. based and how big is it?
- Candesant Biomedical, Inc. is based in Nashville, Arkansas, United States.
- Who are the decision-makers at Candesant Biomedical, Inc?
- Fundz holds 1 contact at Candesant Biomedical, Inc., including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical and Medical Device around the same time
Companies in the same sectors as Candesant Biomedical, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Neochord raised $4.6M (Seed) on June 20, 2023.
- Hubly raised $3M (Seed) on July 21, 2023.
- CathVision raised $9M (Funding Round) on July 18, 2023.
- Hubly raised $5M (Seed) on July 17, 2023.
- CurvaFix raised $39M (Series C) on July 14, 2023.
- INTRINSIC THERAPEUTICS raised $5.5M on July 14, 2023.
Who to call at Candesant Biomedical, Inc., and when
A new round usually means Candesant Biomedical, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Candesant Biomedical, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Candesant Biomedical, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Candesant Biomedical, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Candesant Biomedical, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansCandesant Biomedical, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.